"Zepbound Surpasses Wegovy in Prescriptions as New Weight-Loss Drug"

Prescriptions for Eli Lilly's newly-approved weight-loss drug Zepbound have surpassed those for Wegovy for the first time, with nearly 150,000 new patients filling prescriptions for the shots each week. Zepbound, containing the active ingredient tirzepatide, works by suppressing two appetite-regulating hormones, while Wegovy only acts on one hormone. Market analysts predict the weight loss drug industry to grow to at least $100 billion by the end of the decade, with GLP-1 drugs on pace to surpass cancer immunotherapies as the best-selling medicines.